Shares of Galectin Therapeutics Inc. Common Stock (NASDAQ:GALT) traded down 0.3% on Thursday . The company traded as low as $3.53 and last traded at $3.72. 10,780 shares traded hands during trading, a decline of 99% from the average session volume of 728,033 shares. The stock had previously closed at $3.71.

GALT has been the topic of a number of recent analyst reports. ValuEngine raised shares of Galectin Therapeutics Inc. Common Stock from a “sell” rating to a “hold” rating in a report on Monday, May 14th. BidaskClub raised shares of Galectin Therapeutics Inc. Common Stock from a “buy” rating to a “strong-buy” rating in a report on Friday, June 15th. Finally, HC Wainwright raised their price target on shares of Galectin Therapeutics Inc. Common Stock to $12.00 and gave the company a “buy” rating in a report on Tuesday, May 15th. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $6.94.

The firm has a market cap of $182.83 million, a PE ratio of -7.84 and a beta of 2.29.

Galectin Therapeutics Inc. Common Stock (NASDAQ:GALT) last announced its quarterly earnings results on Tuesday, August 14th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.01). sell-side analysts expect that Galectin Therapeutics Inc. Common Stock will post -0.46 EPS for the current year.

In other news, major shareholder Fund L.P. 10X sold 50,000 shares of the firm’s stock in a transaction dated Monday, June 4th. The shares were sold at an average price of $5.12, for a total transaction of $256,000.00. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Peter G. Traber sold 70,000 shares of the firm’s stock in a transaction dated Friday, June 8th. The shares were sold at an average price of $5.86, for a total transaction of $410,200.00. Following the sale, the chief executive officer now directly owns 177,333 shares in the company, valued at approximately $1,039,171.38. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 1,743,263 shares of company stock worth $11,905,122. Insiders own 45.20% of the company’s stock.

Hedge funds and other institutional investors have recently made changes to their positions in the company. Argent Trust Co purchased a new position in shares of Galectin Therapeutics Inc. Common Stock in the second quarter worth approximately $133,000. Laurel Wealth Advisors Inc. purchased a new position in shares of Galectin Therapeutics Inc. Common Stock in the first quarter worth approximately $101,000. A.R.T. Advisors LLC boosted its holdings in shares of Galectin Therapeutics Inc. Common Stock by 60.2% in the first quarter. A.R.T. Advisors LLC now owns 57,775 shares of the company’s stock worth $273,000 after buying an additional 21,704 shares during the last quarter. LPL Financial LLC purchased a new position in shares of Galectin Therapeutics Inc. Common Stock in the first quarter worth approximately $112,000. Finally, First Allied Advisory Services Inc. purchased a new position in shares of Galectin Therapeutics Inc. Common Stock in the second quarter worth approximately $223,000. 11.87% of the stock is currently owned by hedge funds and other institutional investors.

About Galectin Therapeutics Inc. Common Stock (NASDAQ:GALT)

Galectin Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic disease, skin disease, and cancer. The company's lead product candidate includes galectin-3 inhibitor (GR-MD-02), a galactoarabino-rhamnogalacturonan polysaccharide polymer for the treatment of liver fibrosis and liver cirrhosis in non-alcoholic steatohepatitis patients, as well as for the treatment of cancer.

Further Reading: Fundamental Analysis

Receive News & Ratings for Galectin Therapeutics Inc. Common Stock Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galectin Therapeutics Inc. Common Stock and related companies with MarketBeat.com's FREE daily email newsletter.